Population Pharmacodynamics of IPX066: An Oral Extended-Release Capsule Formulation of Carbidopa-Levodopa, and Immediate-Release Carbidopa-Levodopa in Patients With Advanced Parkinson's Disease

Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease

(2011) Robert A. Hauser et al.   MOVEMENT DISORDERS

Optimizing levodopa therapy for Parkinson’s disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective

(2011) David Brooks   Neuropsychiatric Disease and Treatment

Effects of a Dopamine Agonist on the Pharmacodynamics of Levodopa in Parkinson Disease

(2010) Matthew A. Brodsky et al.   ARCHIVES OF NEUROLOGY

Pharmacokinetic-Pharmacodynamic Modeling of Levodopa in Patients With Advanced Parkinson Disease

(2010) Urszula Adamiak et al.   CLINICAL NEUROPHARMACOLOGY

Levodopa in the treatment of Parkinson’s disease

(2009) A. H. V. Schapira et al.   EUROPEAN JOURNAL OF NEUROLOGY

Levodopa: Past, Present, and Future

(2009) Robert A. Hauser   EUROPEAN NEUROLOGY

Parkinson's disease

(2009) Andrew J Lees et al.   LANCET

The scientific and clinical basis for the treatment of Parkinson disease (2009)

(2009) C. W. Olanow et al.   NEUROLOGY

The Effect of Entacapone on Levodopa Rate of Absorption and Latency to Motor Response in Patients With Parkinson Disease

(2008) Manuela Contin et al.   CLINICAL NEUROPHARMACOLOGY